Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06117774 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
A Phase 3 study of Small-cell Lung Cancer and Limited Stage Small Cell Lung Cancer, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT06117774 is a Phase 3 study of Small-cell Lung Cancer and Limited Stage Small Cell Lung Cancer that is actively recruiting participants, run by Amgen. The registered enrollment target is 400 participants, above the 227-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (76% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT06117774, a Phase 3 study of Small-cell Lung Cancer and Limited Stage Small Cell Lung Cancer, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on blinded independent central review (BCIR) per response evaluation criteria in solid tumors v1.1 (RECIST 1.1) and on prolonging overall survival (OS).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tarlatamab
Study Locations (20)
New York
- New York University Grossman School of Medicine and New York University Langone Hospitals - New York
- Perlmutter Cancer Center at New York University Langone Hospital - Long Island - New York
- Montefiore Einstein Center for Cancer Care - The Bronx
California
- Valkyrie Clinical Trials - Los Angeles
- University of California Los Angeles - Santa Monica
Pennsylvania
- Lehigh Valley Health Network - Allentown
- Spokenword Clinical Trials - Easton
Texas
- Renovatio Clinical - The Woodlands
- US Oncology Research Investigational Products Center - The Woodlands
Virginia
- University of Virginia Health System - Charlottesville
- Virginia Cancer Specialists, PC - Fairfax
Buenos Aires
- Fundacion Respirar - Ciudad Autonoma de Buenos Aires
- Hospital Italiano de La Plata - La Plata
Connecticut
- Yale New Haven Hospital - New Haven
Florida
- Boca Raton Clinical Research Global South Florida - Plantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2030-05-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06117774
The ClinicalTrials.gov registry entry for NCT06117774 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 227-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (76% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06117774 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06117774 about?
NCT06117774 is a clinical study titled "Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)". The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on blinded independent central review (BCIR) per response evaluation criteria in solid tumors v1.1 (RECIST 1.1) and on prolonging overall survival (OS).
What is the current status of trial NCT06117774?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2024-02-20. Estimated completion is 2030-05-29.
What conditions does trial NCT06117774 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer, Limited Stage Small Cell Lung Cancer.
What interventions are being tested in trial NCT06117774?
The interventions under investigation include: Placebo (DRUG), Tarlatamab (DRUG).
Who is sponsoring clinical trial NCT06117774?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06117774 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
RECRUITING · Phase 3
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
ACTIVE NOT RECRUITING · Phase 3
-
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Small-cell Lung Cancer
All registered trials for this condition
Limited Stage Small Cell Lung Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.